Charles Schwab Investment Management Inc Moleculin Biotech, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $429 Billion
  • Q1 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023
BUY
$0.85 - $1.49 $31,115 - $54,542
36,606 New
36,606 $38,000
Q2 2022

Aug 15, 2022
BUY
$1.19 - $2.0 $13,394 - $22,512
11,256 Added 55.73%
31,454 $46,000
Q3 2021

Nov 16, 2021
BUY
$2.7 - $3.59 $54,534 - $72,510
20,198 New
20,198 $61,000
Q2 2021

Aug 16, 2021
SELL
$3.21 - $4.06 $39,056 - $49,398
-12,167 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$3.7 - $6.42 $45,017 - $78,112
12,167 New
12,167 $50,000

Others Institutions Holding MBRX

# of Institutions
2
Shares Held
3.35K
Call Options Held
0
Put Options Held
0
View Full List

About Moleculin Biotech, Inc.

MBRX Quotes by TradingView
  • Ticker MBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,606,700
  • Market Cap $124M
  • Description
  • Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....
More about MBRX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email